Gensight BiologicsFRA:G49N +1.39% Operating Margin % is -1,939.09% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 944 Biotechnology companies, Gensight Biologics ranks worse than 99.79% on this metric.
Gensight Biologics SA operating margin has been in a 5-year decline. The average rate of decline per year is -219.9%.
The historical rank and industry rank for Gensight Biologics's Operating Margin % or its related term are showing as below:
FRA:G49N'
s Operating Margin % Range Over the Past 10 Years
Min: -1105500 Med: -1078.04 Max: -533.07
Current: -1105500
FRA:G49N's Operating Margin % is ranked worse than 99.79% of 944
companies
in the Biotechnology industry
Industry Median: -86.83
vs FRA:G49N: -1105500.00
Gensight Biologics's 5-Year Average Operating Margin % Growth Rate was -219.90% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Gensight Biologics Operating Margin % Related Terms
Gensight Biologics Operating Margin % Historical Data
* Premium members only.
The historical data trend for Gensight Biologics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:G49N vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Gensight Biologics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Gensight Biologics's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Margin % of -1,939.09% mean?
Gensight Biologics (FRA:G49N) has a Operating Margin % of -1,939.09% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Gensight Biologics and its competitors. According to the industry distribution chart, Gensight Biologics ranks #942 out of 944 companies in the Biotechnology industry, placing it in the top 99.8%.
Is Gensight Biologics' Operating Margin % too high?
Gensight Biologics' current Operating Margin % is -1,939.09%. Based on the distribution chart, Gensight Biologics ranks #942 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Gensight Biologics' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #942 out of 944 companies for Operating Margin %. This places Gensight Biologics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Gensight Biologics and its competitors. Gensight Biologics's current Operating Margin % is -1,939.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (FRA:G49N) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.07 — trading 82.8% above its estimated fair value. The current Operating Margin % is -1,939.09%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Gensight Biologics (FRA:G49N), the current Operating Margin % is -1,939.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:G49N has been successfully added to your 